Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.

Background: Despite positive results from phase II and observational studies, Rituximab (RTX) is not currently approved for multiple sclerosis (MS) treatment and can only be used off-label.

Objective: To characterize MS patients treated with RTX and investigate its effectiveness and safety in a clinical practice setting.

Methods: Observational analysis of data collected from MS patients at the Neurocenter of Southern Switzerland.